Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 17/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16563312 | 0.83 | PDE2A (0.49) | PDE2AEPHX2TRPM8 | |
| SCHEMBL16564168 | 0.83 | PDE2A (0.53) | PDE2AEPHX2 | |
| SCHEMBL16563462 | 0.83 | PDE2A (0.53) | PDE2AEPHX2 | |
| SCHEMBL17781275 | 0.82 | PDE2A (0.53) | PDE2A | |
| SCHEMBL16563788 | 0.81 | PDE2A (0.51) | PDE2AEPHX2TRPM8 | |
| SCHEMBL16563806 | 0.81 | MMP12 (0.57) | PDE2AMMP12EPHX2 | |
| SCHEMBL19946337 | 0.78 | PDE2A (0.50) | PDE2AEPHX2TRPM8 | |
| SCHEMBL16563926 | 0.76 | PDE2A (0.57) | PDE2AEPHX2TRPM8 | |
| SCHEMBL16563796 | 0.75 | PDE2A (0.60) | PDE2AEPHX2TRPM8 | |
| SCHEMBL17781232 | 0.75 | PDE2A (0.60) | PDE2AEPHX2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| CN-104245698-B | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-11-30 | — | — | CN | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | PDE2A 1/4885MMP12 1046/4885EPHX2 1190/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | PDE2A 1/4885MMP12 1046/4885EPHX2 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.